Hepatic gluconeogenesis and insulin sensitivity pathways

Hepatic gluconeogenesis and insulin sensitivity pathways represent the integrated metabolic and signaling networks that regulate glucose production in the liver. Gluconeogenesis is the metabolic process of synthesizing glucose from non-carbohydrate precursors like lactate and glycerol, primarily controlled by enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (StatPearls, 2023). Insulin sensitivity refers to the liver's responsiveness to insulin, which normally acts to suppress gluconeogenesis and promote glycogen storage through the PI3K/Akt signaling pathway (Nature Reviews Molecular Cell Biology, 2012). In metabolic diseases like Type 2 diabetes, impaired insulin signaling leads to unrestrained hepatic glucose production, contributing significantly to fasting hyperglycemia (NIH, 2022). Pharmacological intervention aims to restore this balance by enhancing insulin receptor signaling or inhibiting the enzymatic drivers of glucose synthesis, with drugs like metformin acting via AMPK activation to suppress gluconeogenic gene expression (PubChem, 2024). Understanding these integrated pathways is crucial for developing therapies that restore metabolic homeostasis in patients with metabolic syndrome.

Other names

Hepatic glucose production (HGP)Hepatic insulin signalingGluconeogenic pathwayLiver glucose metabolism

Inhibition of hepatic glucose production via AMPK activation, suppression of gluconeogenic enzymes (PEPCK, G6Pase), and enhancement of insulin receptor substrate (IRS) signaling to improve insulin sensitivity.